pdufa.bio

LCAR-B38M CAR-T

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

LCAR-B38M CAR-T is a Legend Biotech Corp program. Its next catalyst is a Readout in Dec 2027. Every date links its source.

LEGN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Legend Biotech Corp (LEGN). We track 2 catalyst events for this program: 1 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jun 2026LEGNReadout · Dec 2027LEGN

Specialist biotech funds holding LEGN, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
EcoR1 Capital800,000$23.1 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is LCAR-B38M CAR-T's next FDA decision or readout?

The next tracked catalyst for LCAR-B38M CAR-T is a Readout in Dec 2027.

What happened at LCAR-B38M CAR-T's most recent FDA decision?

No FDA decision for LCAR-B38M CAR-T is in our archive yet.

Who makes LCAR-B38M CAR-T?

Legend Biotech Corp (LEGN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.